Sharps Technology, Inc. (STSS)
NASDAQ: STSS · Real-Time Price · USD
2.070
-0.050 (-2.36%)
At close: Jan 30, 2026, 4:00 PM EST
2.120
+0.050 (2.42%)
After-hours: Jan 30, 2026, 7:58 PM EST
Company Description
Sharps Technology, Inc., a medical device and pharmaceutical packaging company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States.
The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems.
The company was incorporated in 2017 and is based in Melville, New York.
Sharps Technology, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 14, 2022 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Paul Danner |
Contact Details
Address: 105 Maxess Road, Suite 124 Melville, New York 11747 United States | |
| Phone | 631 574 4436 |
| Website | sharpstechnology.com |
Stock Details
| Ticker Symbol | STSS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.25 |
| CIK Code | 1737995 |
| CUSIP Number | 82003F309 |
| ISIN Number | US82003F3091 |
| Employer ID | 82-3751728 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul Kruger Danner III | Executive Chairman and Principal Executive Officer |
| Andrew R. Crescenzo CPA | Chief Financial Officer |
| Yuwen Zhang | Chief Investment Officer and Director |
| Ben Scheu | Vice President of Sales |
| Frank Parrado | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 26, 2026 | SCHEDULE 13G | Filing |
| Jan 23, 2026 | SCHEDULE 13G/A | Filing |
| Jan 16, 2026 | 8-K | Current Report |
| Jan 16, 2026 | 8-K | Current Report |
| Jan 15, 2026 | SCHEDULE 13G/A | Filing |
| Jan 15, 2026 | SCHEDULE 13G/A | Filing |
| Jan 15, 2026 | SCHEDULE 13G | Filing |
| Jan 13, 2026 | 424B3 | Prospectus |
| Jan 8, 2026 | EFFECT | Notice of Effectiveness |
| Dec 23, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |